Human Inborn Errors of Immunity

A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cellular Immunology".

Deadline for manuscript submissions: 31 August 2024 | Viewed by 97

Special Issue Editor

Department of Infection and Immunity, Luxembourg Institute of Health, Esch-sur-Alzette, 29 rue Henri Koch 4354, Luxembourg
Interests: natural killer cells; immunotherapy; MAIT cells; HLA class I deficiency
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Inborn errors of immunity (IEI), also called primary immune deficiencies (PID), correspond, according to their classic definition, to diseases with an increased susceptibility to infections due to gene mutations affecting the immune system. In recent years, it has become clear that the spectrum of IEI manifestations can also extend to autoimmune, autoinflammatory, allergic or malignant symptoms and biologic abnormalities. The diagnosis of the underlying defect(s) has been greatly facilitated by modern techniques for the exploration of the hematopoietic system and by next-generation sequencing, which has led to the improved recognition of an increased number of such diseases. In parallel, treatment options now include, in many cases, a rather curative approach, such as hematopoietic stem cell transplantation (HSCT) or gene therapy, as well as targeted pharmacological interventions on well-identified cellular processes. This Special Issue of Cells aims to provide an up-to-date overview of the immunological and clinical aspects in the field of IEI [1].


  1. Notarangelo, L.D.; Bacchetta, R.; Casanova, J.L.; Su, H.C. Human inborn errors of immunity: An expanding universe. Sci Immunol. 2020, 5, eabb1662. https://doi:10.1126/sciimmunol.abb1662.

Dr. Jacques Zimmer
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • inborn errors of immunity (IEI)
  • primary immune deficiencies (PID)
  • human
  • immune cells
  • susceptibility to infections
  • pathogens
  • autoimmunity
  • autoinflammation
  • allergy
  • malignancies
  • gene therapy
  • cellular therapy
  • hematopoietic stem cell transplantation (HSCT)
  • pharmacotherapy

Published Papers

This special issue is now open for submission.
Back to TopTop